MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin.
3' Untranslated Regions
Animals
Brain Neoplasms
/ genetics
Cell Line, Tumor
Cell Movement
Cell Proliferation
/ drug effects
Fibronectins
/ genetics
Gene Expression Regulation, Neoplastic
/ drug effects
Glioblastoma
/ genetics
Humans
Male
Mice
MicroRNAs
/ genetics
Neoplasm Transplantation
Prognosis
Survival Analysis
Temozolomide
/ pharmacology
Up-Regulation
/ drug effects
Fibronectin
Glioblastoma
Temozolomide
Tumor suppressor
miR-1
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
28 Nov 2019
28 Nov 2019
Historique:
received:
23
07
2019
revised:
19
08
2019
accepted:
30
08
2019
pubmed:
7
9
2019
medline:
23
5
2020
entrez:
7
9
2019
Statut:
ppublish
Résumé
Glioblastoma (GBM) is a deadly and incurable brain tumor. Although microRNAs (miRNAs) play critical roles in regulating the cancer cell phenotype, the underlying mechanisms of how they regulate tumorigenesis are incompletely understood. We found that miR-1 is expressed at relatively low levels in brain cancer patients, especially GBM. Ectopic miR-1 expression in GBM cells inhibited proliferation and migration, increased sensitivity to apoptosis induced by the DNA alkylating agent temozolomide in vitro, and inhibited GBM tumorigenesis in vivo. Expression of miR-1 in GBM cell lines directly targets fibronectin. High fibronectin expression in GBM correlates with poor patient survival and fibronectin expression is inversely correlated with miR-1 expression. Knockout of fibronectin expression in GBM cell lines inhibited proliferation and migration, increased sensitivity to apoptosis induced by temozolomide in vitro, and markedly suppressed GBM tumor growth and promoted animal survival. In contrast, restoring fibronectin levels in GBM cells ectopically expressing miR-1 increased tumorigenicity and decreased animal survival. Therefore, these results confirm that miR-1 has tumor suppressive activity in GBM by targeting fibronectin, and that the miR-1/fibronectin pathway may be a potential drug target in this devastating cancer.
Identifiants
pubmed: 31491450
pii: S0304-3835(19)30458-6
doi: 10.1016/j.canlet.2019.08.021
pii:
doi:
Substances chimiques
3' Untranslated Regions
0
FN1 protein, human
0
Fibronectins
0
MIRN1 microRNA, human
0
MicroRNAs
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-67Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.